Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Intravaginal Artesunate in Kenya
NCT06263582Phase 1Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in cervical intraepithelial neoplasia (CIN), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve of Dihydroartemisinin at Day 5. Started May 2024; status: completed.
02
Drugs
artesunate
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06263582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263582.